ENLIVEN THERAPEUTICS, INC. Common Stock, Capital Shares Reserved for Future Issuance
ENLIVEN THERAPEUTICS, INC. (ELVN) had Common Stock, Capital Shares Reserved for Future Issuance of 18.67 million shares as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Stockholders' Equity Note › Class of Stock Disclosures
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance · last filed 2026-08-05
- 2026-06-30: Common Stock, Capital Shares Reserved for Future Issuance 18.67M shares.
- 2026-03-31: Common Stock, Capital Shares Reserved for Future Issuance 18.76M shares.
- 2025-12-31: Common Stock, Capital Shares Reserved for Future Issuance 17.54M shares.
- 2025-09-30: Common Stock, Capital Shares Reserved for Future Issuance 16.85M shares.
| Period end | Common Stock, Capital Shares Reserved for Future Issuance | Common Stock, Capital Shares Reserved for Future Issuance as first filed |
|---|---|---|
| 2026-06-30 | 18.67M shares 10-Q · filed 2026-08-05 | |
| 2026-03-31 | 18.76M shares 10-Q · filed 2026-05-07 | |
| 2025-12-31 | 17.54M shares 10-Q · filed 2026-08-05 | |
| 2025-09-30 | 16.85M shares 10-Q · filed 2025-11-12 | |
| 2025-06-30 | 16.88M shares 10-Q · filed 2025-08-13 | |
| 2025-03-31 | 15.38M shares 10-Q · filed 2025-05-14 | |
| 2024-12-31 | 13.28M shares 10-K · filed 2026-03-03 | |
| 2024-09-30 | 13.45M shares 10-Q · filed 2024-11-13 | |
| 2024-06-30 | 12.48M shares 10-Q · filed 2024-08-13 | |
| 2024-03-31 | 9.98M shares 10-Q · filed 2024-05-14 | |
| 2023-12-31 | 7.87M shares 10-K · filed 2025-03-13 | |
| 2023-09-30 | 7.98M shares 10-Q · filed 2023-11-09 | |
| 2023-06-30 | 8.05M shares 10-Q · filed 2023-08-10 | |
| 2023-03-31 | 8.12M shares 10-Q · filed 2023-05-11 | |
| 2022-12-31 | 22.44M shares 10-K · filed 2024-03-14 | 3.07M shares 10-K · filed 2023-02-10 |
| 2022-09-30 | 3.03M shares 10-Q · filed 2022-10-25 | |
| 2022-06-30 | 2.75M shares 10-Q · filed 2022-08-03 | |
| 2022-03-31 | 1.87M shares 10-Q · filed 2022-05-06 | |
| 2021-12-31 | 21.70M shares 8-K · filed 2023-06-23 | 1.39M shares 10-K · filed 2022-03-15 |
| 2021-09-30 | 1.46M shares 10-Q · filed 2021-11-09 | |
| 2021-06-30 | 1.57M shares 10-Q · filed 2021-08-06 | |
| 2021-03-31 | 1.68M shares 10-Q · filed 2021-05-11 | |
| 2020-12-31 | 1.30M shares 10-K · filed 2022-03-15 | |
| 2020-09-30 | 1.47M shares 10-Q · filed 2020-11-05 | |
| 2020-06-30 | 1.51M shares 10-Q · filed 2020-08-14 | |
| 2020-03-31 | 1.39M shares 10-Q · filed 2020-05-07 | |
| 2019-12-31 | 9.84M shares 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |